我国慢性丙型病毒性肝炎筛查与治疗的医疗费用

Analysis of Medical Expenses for Chronic Hepatitis C Screening and Treatment in China

目的分析如何实现"2030消除丙肝"的目标及其对医疗费用支出造成的影响。方法以统计年鉴、公开发表的论文、临床实践及专家意见等为基础,测算干预/不干预情况下,2021—2030年我国慢性丙型病毒性肝炎患者的累积诊断率及治疗率。结果需要提高慢性丙型病毒性肝炎诊断率和治疗率以实现"2030消除丙肝"的目标,相关医疗费用支出总计582.33亿元,但后续10年内进展为代偿性肝硬化、失代偿性肝硬化、肝癌、肝移植、死亡的累计发生分别减少860140、110 714、42 616、5 974以及216 215人次,相应的疾病进展总治疗费用减少919.41亿元;共计减少医疗卫生支出337.08亿元。结论提高慢性丙型病毒性肝炎诊断率及治疗率,将减少我国慢性丙型病毒性肝炎的医疗卫生支出,有助于快速实现"2030消除丙肝"的目标。

Objective To analyze how to achieve the target of " Hepatitis C Virus Elimination by 2030" and measured its impact on medical expenses. Methods Based on the statistical yearbook, published papers, clinical practice and expert opinions, the cumulative diagnostic rate and treatment rate of CHC patients in China from 2021 to 2030 with or without intervention was calculated. Results It was necessary to increase the diagnosis rate and treatment rate of CHC to achieve the goal of " Hepatitis C Virus Elimination by 2030", the total related medical expenses would be 58.233 billion yuan. However, the cumulative number of patients with compensatory cirrhosis, decompensatory cirrhosis, liver cancer, liver transplantation and death would be reduced by 860 140, 110 714, 42 616, 5 974 and 216 215 respectively, the corresponding total treatment cost of disease progression would be reduced by 91.914 billion yuan, and the total medical and health expenditure would be reduced by 33.708 billion yuan. Conclusion Improving the diagnosis and treatment rate of CHC will reduce the medical and health expenditure of CHC, which will help to achieve the target of " Hepatitis C virus elimination by 2030".